Spotlight on the utility of the Oncotype DX(®) breast cancer assay

The Oncotype DX(®) assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. It has ushered in the era of genomic-based personalized cancer care for ER-positive primary breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Siow, Zhen Rong, De Boer, Richard H, Lindeman, Geoffrey J, Mann, G Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827461/
https://www.ncbi.nlm.nih.gov/pubmed/29503586
http://dx.doi.org/10.2147/IJWH.S124520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827461/
https://www.ncbi.nlm.nih.gov/pubmed/29503586
http://dx.doi.org/10.2147/IJWH.S124520

Ejemplares similares